Introduction
Following the introduction of the National Health Service and Community Care Act (1990), it became apparent that the pathology services in the United Kingdom would have to function in a more commercial manner. This participation in the "open market" was, for the most part unexpected. Several "resource management sites" had been established at major hospitals in England with consequent injection of information technology and accompanying financial expertise. However, most pathology managers (usually medically qualified consultants) and the financial officers associated with their hospital units were unprepared for the amount of costing information required of them. In the past there had been little work carried out on costing in the NHS because there was no perception of the need for such data, although microcomputer software to assist costing had been described.'
One stimulus to obtain the necessary information was the tasking of the National Audit Commission to look at the "value-for-money" aspect of pathology services.2 To this end the Commission developed their own software and methodology of costing. These programs required certain data items from the laboratories, but often this information was difficult to obtain, primarily because of lack of information technology and a paucity of firm financial information at the laboratory level. However, what has finally emerged is a "snapshot" of the pathology services from which comparisons can be made against the national average for a number of costed tests in the four main pathology disciplines of haematology and blood transfusion, clinical chemistry, microbiology and histopathology.
But this exercise was imposed on the pathology services with the pre-defined goal of obtaining information pertinent to "value", such as why should the blood count 10 miles away at hospital X cost 50% more than at hospital Y? Although the final report highlighted potential problems, it produced little data of day-to-day managerial use. Since an axiom of systems analysis is to "define your outputs before your inputs" we might ask what information is required by pathologists with regard to pathology costing?
What costing information is required Why cost at all? At present NHS hospitals allocate an annual budget to their laboratory service. Traditionally this has been a "topdown" budget into which we squeeze the demands on the service. Unfortunately the laboratories are demand-led, with pathologists having little control over the increasing requirements of the clinical services for pathology investigations. Our haematology laboratory has seen the annual number of test requests rise by 3-4% in 1989-90 and by 10% in 1990-91. Because these services have been supplied without charge to the purchasing clinical services, "market forces" have had no part to play in controlling laboratory use. The introduction of the "purchaser-provider" roles with contractual obligations has altered all this. General practitioners who have recently elected to manage their own budgets can now request laboratory tests wherever they want. Suddenly there is the need for information about laboratory test costs so that budgets for the use of the laboratory by these primary care doctors can be determined. So do we need to know individual test costs? Although it has been suggested that this practice should be avoided, this is primarily on grounds of the necessity for frequent recalculation as prices of consumables or salaries A pragmiatist's approach to pathology, costinig: the Welsh Datatree project change.3 Indeed, it was suggested that if individual test costs were required then they should mirror those prices published by private pathology laboratories. However, the Audit Commission has demonstrated the difference between NHS laboratory costs and private laboratory prices of the commoner high volume pathology tests. The difference in price may be for recapitalising of the laboratory, but are the NHS laboratories going to be allowed to adopt this process? It seems extremely doubtful at present because it would necessitate the carrying over of profits for several years to accrue the necessary budget for purchase of new equipment. A possible solution would be for the districts to set up capital funding programmes for the purchase of new laboratory equipment. This is already in place and working well in some districts.
Any information on costing will have a profound effect on the running of our laboratories. 
Salary information can be obtained either from the end of year budget statement or direct from the finance officers. However, all oncosts must be included. Even so, there still exists the problem of building into the costing system a method to allow for pay rises and for probable backdating of the pay awards.
Capital depreciation in the Health Service has never been fully defined, and it has usually been the opportunity for a replacement machine that defines the life of any replaced equipment. Few districts have had the foresight to set up capital programs for replacement of pathology equipment. So the amortisation period has been rather haphazard and variable between pieces of equipment and between laboratories.
The introduction of capital charges has changed all this. The definition of a capital asset is "a tangible asset which is capable of being used in an authority's activities for a period which could exceed one year." Each laboratory will have an asset register containing the equipment deemed to be affected by capital charges. Although the calculations are complicated, there should be individualised capital charges available for each piece of equipment. This yearly charge can be input into the laboratory costing package.
The pragmatic approach to costing For several years Welsh pathology laboratories have been interested in workload measurements. It was not suprising, therefore, that with the introduction of the NHS white paper and the changes that it suggested in the relationship between pathology laboratories and their purchasers, that a project should be established to investigate the costing of pathology. Rudimentary costing methods were presented at a joint meeting with representatives from the Welsh Office and the "value-formoney" unit, a directorate of the Welsh Office in early 1991. At this meeting pathologists from Glan Clwyd Hospital presented the Datatree costing program. This is a commercial costing package used in manufacturing and industry for several years, but at that time with no applications in the NHS. The meeting was impressed at the potential of the Datatree media used at each workstation needs to be estimated. Histopathology Histopathology departments perform one investigation (a histopathological examination) on possibly in excess of 300 types of tissue specimen. Coupled with the fact that the work done on each specimen may vary considerably in any department because of local working practice, the problems are compounded. In histopathology fixed and variable costs do not feed directly into the specimen trees, but rather into subtrees created to cost procedures, such as staining, tissue processing, etc. These processes can be weighted depending on previous workload and local practice, producing costs which reflect the complexity of a histological investigation in a given department.
Cervical cytology can be treated similarly, the procedures feeding into trees which take into account two-smear cases, hormonal evaluation, abnormal recall, as well as positive and negative smears, thereby producing a single volume sensitive cost for a cervical smear.
Specialised procedures such as electron microscopy, immunocytochemistry, and resin processing techniques, are all catered for by this costing method. 
